What is Capivasertib Tablet?

Capivasertib is an investigational oral AKT inhibitor, used primarily in combination with Fulvestrant to treat hormone receptor-positive (HR+), HER2-negative advanced or metastatic breast cancer. It works by targeting a protein involved in the PI3K/AKT signaling pathway, which plays a crucial role in the growth and survival of cancer cells.

How Capivasertib Tablet Works

Capivasertib is a selective AKT inhibitor that works by blocking the activity of AKT enzymes. The AKT signaling pathway is often overactive in many cancers, promoting uncontrolled tumor cell proliferation, survival, and resistance to treatment.
By inhibiting AKT, Capivasertib helps:
Suppress tumor cell growth
Enhance sensitivity to other treatments like hormonal therapies
Improve patient response in cancers with specific genetic mutations

Side Effects of Capivasertib Tablet:

Capivasertib Tablets, like many targeted cancer therapies, may cause certain side effects that vary in severity. Common side effects include diarrhea, skin rash, nausea, fatigue, and reduced appetite. Some patients may also experience more serious effects such as elevated blood sugar levels, liver enzyme changes, infections, or mouth sores.

Disclaimer
RxLane provides information for educational purposes only. All trademarks, brands, and service marks are the property of their respective owners. RxLane does not offer medical advice. Please consult your doctor for appropriate diagnosis and treatment. This content is intended for wholesalers, doctors, hospitals, clinics, pharmacies, and medical institutions.